Published in
American Association for the Advancement of Science, Science Translational Medicine, 396(9), 2017
DOI: 10.1126/scitranslmed.aal3694
Links
Tools
Type 2 immunity is protective in metabolic disease but exacerbates NAFLD collaboratively with TGF-β
Journal article published in 2017 by
Kevin M. Hart 
,
Thomas Fabre ,
Joshua C. Sciurba ,
Richard L. Gieseck ,
Lee A. Borthwick,
Kevin M. Vannella,
Thomas H. Acciani ,
Rafael de Queiroz Prado,
Robert W. Thompson ,
Sandra White ,
Genevieve Soucy,
Marc Bilodeau,
Thirumalai R. Ramalingam,
Joseph R. Arron ,
Naglaa H. Shoukry
and other authors.
,
Thomas Fabre ,
Joshua C. Sciurba ,
Richard L. Gieseck ,
Lee A. Borthwick,
Kevin M. Vannella,
Thomas H. Acciani ,
Rafael de Queiroz Prado,
Robert W. Thompson ,
Sandra White ,
Genevieve Soucy,
Marc Bilodeau,
Thirumalai R. Ramalingam,
Joseph R. Arron ,
Naglaa H. Shoukry
and other authors.
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 
Abstract
Development of NASH fibrosis is accompanied by accumulation of hepatic eosinophils and driven by TGF-β and profibrotic type 2 inflammation.